Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2025 value amounting to $38.5 million.

  • Iovance Biotherapeutics' Cost of Revenue rose 22.08% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.4 million, marking a year-over-year increase of 186.42%. This contributed to the annual value of $124.0 million for FY2024, which is 1052.91% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cost of Revenue stood at $38.5 million for Q3 2025, which was down 32.10% from $56.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Cost of Revenue's 5-year high stood at $68.5 million during Q4 2024, with a 5-year trough of $4.3 million in Q3 2023.
  • In the last 3 years, Iovance Biotherapeutics' Cost of Revenue had a median value of $31.5 million in 2024 and averaged $32.5 million.
  • Data for Iovance Biotherapeutics' Cost of Revenue shows a peak YoY surged of 1,470.13% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Cost of Revenue (Quarterly) stood at $4.4 million in 2023, then soared by 1,470.13% to $68.5 million in 2024, then grew by 22.08% to $38.5 million in 2025.
  • Its Cost of Revenue was $38.5 million in Q3 2025, compared to $56.7 million in Q2 2025 and $49.7 million in Q1 2025.